mFluiDx, Inc. is a Berkeley-based company that specializes in the development of rapid and fully automated point-of-care diagnostic tests for outpatient clinics. With a focus on nucleic acid amplification, mFluiDx aims to address the limited availability of low-cost FDA cleared products for primary care settings. Their innovative microfluidic technology allows for the quick and accurate detection of target pathogens that are difficult to differentiate based on symptoms alone, providing healthcare professionals with valuable diagnostic tools.
Through their participation in SBIR Phase I and Phase II programs, mFluiDx has received funding from the Department of Health and Human Services National Institutes of Health to support their research and development efforts. Their commitment to advancing point-of-care diagnostics for primary care settings showcases their dedication to improving patient outcomes and revolutionizing the field of outpatient healthcare.
Generated from the website
